Peptides DB
Research-centric peptide and protocol reference hub

Buserelin record · updated 6h ago

Healing & recoveryMetabolic & appetiteGrade B · human evidenceResearch use only
All 10 studiesJump to the evidenceCompare
What is Buserelin used for?

Research peptide discovered via AI researcher. peptide analogue

Primarily researched for · Healing & recovery

Development stage

where Buserelin sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 41 registered trials. It describes the research record, not a recommendation.

Identity
NameBuserelin
Chain length—
Molecular weight1,239.4 Da
FormulaC60H86N16O13
Structure typeNot established
ClassHealing
Research levelWell Studied
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 50225. No verified residue count for this compound.

Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 20, 2026. How this works →
Research stats
Total studies10
Human / animal / cellular4 / 5 / 0
Highest trial phase—
Years covered2023–2026
Latest study2d ago
Publication history
20232026
Research funding
33 NIH projects · $3.0M awarded · through FY2008
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports151
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

10 rowsOpen in the library →
StudyTypeYearSummary depth
Intravaginal GnRH analogues in rabbits: Fertirelin as the most effective option for ovulation induction.
FindingFertirelin achieved ovulation and delivery rates equivalent to the intramuscular control at a dose of 1 μg.
Animal2026Full text read0.80
Surveillance for <i>Coxiella burnetii</i> animal reservoirs in Hong Kong suggests low zoonotic risk of Q-fever from local animals including ruminants, companion animals and rodents.
Finding0% C. burnetii DNA detected in 866 animals.
Animal2026Full text read0.90
Biosensor capability of the endometrium is mediated in part, by altered miRNA cargo from conceptus-derived extracellular vesicles
Finding1153 DEGs between in vivo and in vitro conceptuses.
Animal2023Full text read0.70
Evaluation of the Ovsynch and Co-synch protocols on estrus intensity and pregnancy rate in Anatolian buffalo heifers
FindingPregnancy rates were 30% and 75% in the Ovsynch and Cosynch groups, respectively (P<0.05).
Animal2024Full text read0.80
Adverse Event Profile Differences among Long-acting Gonadotropin-releasing hormone analogs: A Real-world, Pharmacovigilance Study
FindingNot reported in abstract.
review2024Full text read0.70
Use of EC-GnRH34 timed AI protocol in crossbred Girolando dairy cows
FindingCows in the EC-GnRH34 group ovulated at 60.4 ± 3.8h, P = 0.03.
Animal2025Full text read0.80
The influence of serum Luteinising hormone concentrations post GnRH agonist trigger on metaphase II oocytes in IVF/ICSI cycles
FindingMean LH level at 12 hours post trigger was 34.05 (SD 23.07 IU/L, range: 0.9 to 134.4 IU/L).
Human2025Full text read0.80
Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH.
FindingMedian AMH levels at baseline were 6.21 ng/ml in the PCOM group vs 1.7 ng/ml in the non-PCOM group, p<0.001.
Human2026Full text read0.80
Oocyte maturation and pregnancy outcomes in relation to gonadotropin duration in antagonist cycles.
FindingAdjusted OR 1.07 for oocyte maturation per day of Gn stimulation, 95% CI 1.05-1.09, p<0.001.
Human2026Full text read0.90
Efficacy and safety of combined GnRH-a, hysteroscopic surgery, and LNG-IUS for adenomyosis with suboptimal HIFU ablation: a retrospective study.
FindingMedian NPV ratio following HIFU ablation was 22.2% (IQR: 12.0%-36.2%)
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Buserelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Buserelin is discussed should be drawn from it.